News
Dupixent hits all endpoints in prurigo nodularis trial
Sanofi and Regeneron’s monoclonal antibody (mAb) Dupixent (dupilumab) met all primary and key secondary endpoints in a Phase III trail for the chronic inflammatory skin disease prurigo nodularis.